Docetero 120mg Injection
Rx RequiredSalt Composition: Docetaxel Injection IP
Expiry Date: 01/2028
Buy at $80.84
Inclusive of all taxes
1 Injection
About The Product
Lung, prostate, bladder, ovarian, breast, head and neck cancer
Description
Docetero 120mg Injection is a doctor prescribed, an anticancer conventional therapeutic injection. It is primarily used to treat Breast Cancer, Lung Cancer, Prostate Cancer, Stomach cancer and Head/Neck Cancer.
Docetero Injection contains Docetaxel, chemical based salt. It is a semi-synthetsic taxane chemotherapy agent that stabilises microtubules and disrupting cell division in rapidly proliferating cancer cells.
Indication
Breast Cancer, Lung Cancer, Prostate Cancer, Stomach cancer and Head/Neck Cancer
Dosage And Administration
- The dosage of Docetero 120mg Injection depends on the cancer type, its stage and pateint's overall health.
- For exact personalized dosage visit to your doctor for consultation.
- Docetero 120mg Injection is administered intravenously (In Veins) by a doctor or a professional and experienced nurse.
- Do not self administer the injection.
Mechanism Of Action
Docetero 120mg Injection contains Docetaxel, chemical based salt.
It is a semi-synthetsic taxane chemotherapy agent that reversely binds to tubulin with high affinity, promoting microtubule polymerization and inhibiting its polymerization which disrupts micro tubular dynamics and its structure.As a result, by stabilising microtubules and disrupting cell division in rapidly proliferating cancer cells.
Safety Advice
Faqs
Yes, there are severe side effects of Docetero 120mg Injection.
Side effects include Severe Fluid Retention, Liver Toxicity, Blood Clots, Serious Skin reactions, Penumonitis, Severe Allergic Reaction, Febrile Neutropenia etc.
References
• Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S., & von Minckwitz, G.
(2009). Docetaxel-related side effects and their management.
European journal of oncology nursing, 13(1), 49-59. • Ho, M. Y., & Mackey, J.
R. (2014).
Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer management and research, 253-259. • Cortes, J.
E., & Pazdur, R. (1995).
Docetaxel. Journal of Clinical Oncology, 13(10), 2643-2655. • Clarke, S.
J., & Rivory, L. P.
(1999). Clinical pharmacokinetics of docetaxel.
Clinical pharmacokinetics, 36(2), 99-114.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
